These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21208841)

  • 21. Predictive markers for colorectal cancer: current status and future prospects.
    Longley DB; McDermott U; Johnston PG
    Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New and potential clinical applications of KRAS as a cancer biomarker.
    Kriegshäuser G; Auner V; Zeillinger R
    Expert Opin Med Diagn; 2010 Sep; 4(5):383-95. PubMed ID: 23496197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.
    Clarke SJ; Karapetis CS; Gibbs P; Pavlakis N; Desai J; Michael M; Tebbutt NC; Price TJ; Tabernero J
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):121-35. PubMed ID: 22762963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
    Custodio A; Barriuso J; de Castro J; Martínez-Marín V; Moreno V; Rodríguez-Salas N; Feliu J
    Cancer Treat Rev; 2013 Dec; 39(8):908-24. PubMed ID: 23510598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.
    Foroughi S; Tie J; Gibbs P; Burgess AW
    Growth Factors; 2019 Dec; 37(5-6):209-225. PubMed ID: 31878812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers and targeted therapeutics in colorectal cancer.
    Meguerditchian AN; Bullard Dunn K
    Surg Oncol Clin N Am; 2013 Oct; 22(4):841-55. PubMed ID: 24012402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
    Sridharan M; Hubbard JM; Grothey A
    Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Therapy of Colorectal Cancer.
    Seeber A; Gastl G
    Oncol Res Treat; 2016; 39(12):796-802. PubMed ID: 27889786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular markers for colon diagnosis, prognosis and targeted therapy.
    Herzig DO; Tsikitis VL
    J Surg Oncol; 2015 Jan; 111(1):96-102. PubMed ID: 25297801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management.
    Lieu CH; Corcoran RB; Overman MJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():207-215. PubMed ID: 31099678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel biomarkers for the prediction of metastasis in colorectal cancer.
    Zlobec I
    Expert Opin Med Diagn; 2013 Mar; 7(2):137-46. PubMed ID: 23530884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF-mutant colorectal cancer, a different breed evolving.
    Lai E; Pretta A; Impera V; Mariani S; Giampieri R; Casula L; Pusceddu V; Coni P; Fanni D; Puzzoni M; Demurtas L; Ziranu P; Faa G; Scartozzi M
    Expert Rev Mol Diagn; 2018 Jun; 18(6):499-512. PubMed ID: 29708446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
    Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
    World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
    Taieb J; Jung A; Sartore-Bianchi A; Peeters M; Seligmann J; Zaanan A; Burdon P; Montagut C; Laurent-Puig P
    Drugs; 2019 Sep; 79(13):1375-1394. PubMed ID: 31347092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Right drug for the right patient": hurdles and the path forward in colorectal cancer.
    Kopetz S
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating biomarkers into clinical decision making for colorectal cancer.
    Wilson PM; Lenz HJ
    Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S16-27. PubMed ID: 20630847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.